retatrutide phase 2 results 2024 2025 study sees significant weight loss in obesity drug study Phase 2 trial results demonstrate

When it becomes an approved option, retatrutide may be offered as a triple agonist weight loss treatment within a supervised program

Although, most participants lost weight, there was heterogenicity, that has been well-documented in obesity studies [66] and those with higher BMI above 35 experienced greater mean percentage weight loss [64]

Furthermore, a recent extensive cohort study involving over 33,000 GLP-1 RA users diagnosed with diabetes over a 9-year period indicated no significant increase in pancreatic cancer risk associated with GLP-1 RA use, as evidenced by an HR of 0.50 compared to basal insulin [60]

The math is not complicated, but getting it wrong means the difference between an effective protocol and weeks of wasted time

Although GLP-1/triple agonists show metabolic benefits [4,6], their effects on weight loss remain limited in insulin-deficient STZ models [25]

YOUR TREATMENT TIMELINE Most patients with back pain attend physical therapy two to three times per week